Announcement PDF ASX Announcement 29 July 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 Cleansing Notice under section 708A(5)(e) of the Corporations Act This notice is given by Microba Life Sciences Limited (ASX: MAP) (“Microba” or “the Company”) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). On 12 June 2026, Microba announced a capital raise to the ASX consisting of: • Placement - a placement to raise $5.0 million before costs by the issue of 100,004,240 ordinary shares (New Shares) at $0.05 per New Share, plus 100,004,240 free-attaching options (New Options) on the basis of one (1) New Option for every one (1) New Share subscribed for under the placement (Placement). The Placement has completed in two tranches, with 91,344,455 New Shares being issued under tranche 1 of the Placement (Tranche 1 Placement Shares) and 8,659,785 New Shares being issued under tranche 2 of the Placement (Tranche 2 Placement Shares). • Share Purchase Plan - a share purchase plan offered to eligible Microba shareholders to raise up to a further $1.0 million before costs by the issue of up to 20,000,000 New Shares at $0.05 per New Share, plus up to 20,000,000 free-attaching New Options on the basis of one (1) New Option for every one (1) New Share subscribed for under the share purchase plan (SPP Offer). The Tranche 1 Placement Shares were issued on 18 June 2026 and an Appendix 2A has been lodged with the ASX for quotation of those Tranche 1 Placement Shares. The SPP Offer opened on 19 June 2026 under a prospectus lodged with ASIC on 19 June 2026 and closed on 22 July 2026. Valid applications were received for 8,150,000 New Shares, raising $407,500 before costs. Those New Shares, and 8,150,000 free-attaching New Options, were issued on 29 July 2026, and an Appendix 2A has been lodged with the ASX for quotation of those New Shares. The New Shares issued under the SPP Offer were issued under a prospectus and are not the subject of this notice. The Tranche 2 Placement Shares and all New Options for both tranches of the Placement were issued on 29 July 2026 and an Appendix 2A has been lodged with the ASX for quotation of the Tranche 2 Placement Shares. Details of the Tranche 2 Placement Shares Details of the issue of Tranche 2 Placement Shares are provided below: Class of Securities: Fully paid ordinary shares ASX Code of the securities: ASX : MAP Date of the issue: 29 July 2026 Total number of Tranche 2 Placement Shares: 8,659,785 In accordance with section 708A(6) of the Corporations Act, Microba gives notice that: • the Tranche 2 Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act; • this notice is being given under section 708A(5)(e) of the Corporations Act; • as of the date of this notice, the Company has complied with: o the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and o sections 674 and 674A of the Corporations Act; and ASX Announcement 29 July 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 • as of the date of this notice, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company. FY26 audit and financial statements Microba's external audit for the financial year ended 30 June 2026 is in progress and the FY26 financial statements are subject to finalisation of that audit. Microba's regional break-even guidance is subject to the same process and will be released alongside the FY26 Annual Report, which is expected in late August 2026. All material financial information presently known to the Directors was released as part of the Quarterly Report and Appendix 4C on 16 July 2026. This announcement has been authorised for release by the Board of Directors. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com